Purdue Innovators Use Funding to Advance Technologies
Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowSix Purdue University researchers have received a total of more than $200,000 from the Trask Innovation Fund to help their labs commercialize their innovations, four of which are in medical enhancements.
The fund, awarded twice a year, is a development program established to support projects that advance the commercial value of Purdue intellectual property.
It intends to aid faculty and staff with their patented innovations that are being commercialized through the Purdue Research Foundation Office of Technology Commercialization.
“Researchers submitted a lot of technologies worthy of OTC’s investment to create solutions through the Purdue commercialization ecosystem and Purdue’s growing Discovery Park District,” said Abhijit Karve, director of business development for the Purdue Office of Technology Commercialization.
The Purdue researchers receiving funding this round:
- Young Kim, Scalable production and deposition of luminescent silk microparticles for ‘on-dose’ medicine authentication.
- Pavlos Vlachos, Automated analysis for improved heart health.
- Philip Low, Development of targeted therapies for idiopathic pulmonary fibrosis.
- Yoon Yeo, Abxtal for cancer immunotherapy.
- James Caruthers, Composite board binder systems from rice lignin.
- Arman Sabbaghi, Enhancing the commercial value of AMapi: An API for additive manufacturing systems.
Click here to learn more about the Trask Innovation Fund.